SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending, with community members actively discussing its potential for significant gains and highlighting its availability on platforms like Coinbase. Some users are suggesting it as an alternative investment and pointing to company updates. However, others are questioning its current performance and debating its valuation.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA) is trending as the community anticipates the mainnet launch this month and a potential Coinbase listing. Speculation is high regarding partnerships and the impact of anchored technology, with some touting its potential to revolutionize finance and replace XRP. Despite some expressing concerns about a potential "sell the news" event, the community remains largely bullish on Keeta's prospects.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending as the community highlights accumulation by early investors. Attention appears to be driven by calls to buy before a potential surge. Community members are encouraging others not to miss out on the opportunity.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending as the community debates its potential following news of continued development and partnerships. Some traders express frustration with price action and question the project's value, while others remain optimistic, citing long-term potential and accumulating more coins. Discussions also revolve around the broader market trends and their impact on JASMY's performance.

Levi Strauss & Co. engages in the design, marketing, and sale of apparel products. The company offers jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories. It operates through the following geographical segments: Americas, Europe, and Asia. The company was founded by Levi Strauss in 1853 and is headquartered in San Francisco, CA.

Levi Strauss & Co. - Ordinary Shares Cls A

LEVI is trending as the community discusses the company's recent earnings report and revised outlook, with some pointing to potential headwinds from tariffs. Bullish investors highlight the long-term uptrend and potential breakout patterns, while others express concern about the impact of current macroeconomic conditions and a potential sale of the Dockers brand. Community members are also debating the effectiveness of the company's marketing strategy, including its partnership with Beyonc.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as the company prepares to release earnings, with analysts weighing in on potential growth drivers like digital expansion and menu innovation. Some traders are mapping out options strategies, while others debate whether the stock can maintain its upward trajectory amidst concerns about consumer spending and potential headwinds. The return of value-focused meals may be a catalyst as the company looks to maintain its image of affordable dining.

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Cardinal Health, Inc.

Cardinal Health ($CAH) is trending due to renewed investor optimism, driven by increased FY24 EPS guidance and confidence in the pharmaceutical segment's growth.  Community discussions highlight the potential for continued upside, particularly with strong performance and strategic initiatives.  Positive analyst ratings and a new share repurchase authorization further contribute to the bullish sentiment surrounding the stock.

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences Corp

Edwards Lifesciences is trending amid discussions around its Q3 earnings potential and recent analyst ratings. Community members are weighing the prospects of TAVR growth and valve therapies driving results, while also noting unusual options activity and potential technical violations. Recent news and reports provide mixed signals, contributing to active debates about the stock's near-term direction.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Hologic, Inc.

Hologic is trending following renewed takeover interest from Blackstone and TPG, potentially valuing the women's health medical device company at over $17 billion. Community members are actively discussing potential acquisition prices and the likelihood of a deal, with some analysts adjusting their price targets accordingly. Hologic's focus on women's health and recent FDA clearances are also contributing to the stock's momentum.

Verisk Analytics, Inc. engages in the provision of data, analytics, and technology services. The firm also offers predictive analytics and decision support solutions to clients in rating, underwriting, claims, catastrophe, and weather risk fields. It operates through the Insurance segment. The Insurance segment offers fraud-detection solutions including review of data on claim histories, analysis of claims to find emerging patterns of fraud, and identification of suspicious claims in the insurance sector and offers solutions and services primarily through annual subscriptions or long-term agreements. The company was founded in 1971 and is headquartered in Jersey City, NJ.

Verisk Analytics Inc

Verisk Analytics (VRSK) is trending amid rating updates from various firms, with price target adjustments reflecting mixed sentiment. Community discussions revolve around potential upsides and downsides, with some focusing on its AI-powered tools and analytics in the insurance sector. Additionally, several alerts have been released regarding call options for VRSK.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now

Inventiva (IVA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%

The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Inventiva secures 94.1M in financing, potentially reaching 348M, to fund the Phase 3 NATiV3 trial for lanifibranor in NASH. Leadership changes include new chairman and director appointments.
read...

Inventiva Advances Lanifibranor Trial with Promising Data

Inventiva (IVA) has released an update. Inventiva reports strong progress in its NATiV3 Phase III clinical trial for lanifibranor, with over 80% en...

FY2025 Earnings Forecast for Inventiva S.A. (NASDAQ:IVA) Issued By HC Wainwright

Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Inventiva in a report issued on Monday...

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States), April 3, 2024 Inventiva (Euronext Paris and Nasdaq: IVA) (the Company ), a clinical-stage biopharmaceutical company focused on the...

Brokerages Set Inventiva S.A. (NASDAQ:IVA) Price Target at $15.67

Inventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average recommendation of "Buy" by the eight brokerages that are covering the firm, MarketBeat.com reports. Eight investment analysts...

Buy Rating Affirmed: Inventiva's Progress and Promise in Lanifibranor's Clinical Trials

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Inventiva (IVA Research Report), retaining the price target of $22.00. Ed Arce has...

Full Year 2023 Inventiva SA Earnings Call Transcript

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Inventiva - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

IVA
Inventiva - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IVA News

IVAInventiva - ADR